Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19.

Shapiro, Adrienne E; Bender Ignacio, Rachel A

Shapiro, Adrienne E; Bender Ignacio, Rachel A.

Shapiro AE; Department of Global Health and Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98104, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: aeshapir@uw.edu.
Bender Ignacio RA; Department of Global Health and Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98104, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Lancet Infect Dis ; 22(5): 567-569, 2022 05.

Article in English | MEDLINE | ID: covidwho-1967519

Subject(s)

Antineoplastic Agents, Immunological; COVID-19; Antibodies, Monoclonal/therapeutic use; Hospitalization; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / COVID-19 Limits: Humans Language: English Journal: Lancet Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google